证券代码：002880 证券简称：卫光生物 公告编号：2025-046 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 √否 登录新浪财经APP 搜索【信披】查看更多考评等级 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况： □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 二、股东信息 （一） 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 单位：股 ■ 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 ...

格隆汇10月30日丨卫光生物(002880.SZ)发布公告，2025年前三季度，实现营业收入7.91亿元，同比减少 7.40%；归属于上市公司股东的净利润1.58亿元，同比减少13.60%；归属于上市公司股东的扣除非经常 性损益的净利润1.55亿元，同比减少12.67%；基本每股收益0.696元。 ...

智通财经APP讯，卫光生物(002880.SZ)发布2025年三季度报告，前三季度，公司实现营业收入7.91亿 元，同比下降7.40%。归属于上市公司股东的净利润1.58亿元，同比下降13.60%。归属于上市公司股东 的扣除非经常性损益的净利润1.55亿元，同比下降12.67%。 ...

卫光生物成立于1986年4月7日，于2017年6月16日在深圳证券交易所上市，注册地址和办公地址均为广东 省深圳市。该公司是国内血液制品领域的重要企业，专注于血液制品生产经营及药物研发，拥有较高的技 术壁垒和丰富的产品线。 卫光生物主营业务为血液制品的生产经营及药物研发，所属申万行业为医药生物 - 生物制品 - 血液制品， 所属概念板块有小盘、血液制品、合成生物核聚变、超导概念、核电。 截至2025年9月30日，卫光生物A股股东户数为1.25万，较上期减少0.70%；户均持有流通A股数量为1.81 万，较上期增加0.70%。十大流通股东中，香港中央结算有限公司位居第九大流通股东，持股67.94万股， 为新进股东。 华安证券指出，2024年公司营收、利润双增长，扣非净利润增速亮眼。业务亮点如下：1. 全年业绩稳健增 长，扣非净利润增速高于营收和归母净利润增速；2. 费用管控效果显著，盈利能力有所提升；3. 主营业务 稳健增长，核心产品表现优异，采浆量持续提升；4. 产品线进一步丰富，提升血浆利用率；5. 卫光生命科 学园运营提质增效，带动物业出租业务高速增长。该机构预计公司2025 - 2027年营收分别为 1 ...

公告显示，公司前三季度营业收入790,899,107.60元，同比减少7.4%，归属上市公司股东的净利润 157,860,537.25元，同比减少13.6%。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 10月30日消息，卫光生物发布三季度报告。 责任编辑：小浪快报 公告显示，十大流通股东中，深圳市卫光生物制品股份有限公司－第三期员工持股计划、香港中央结算 有限公司、聂海燕为新进流通股东。 ...

南财智讯10月30日电，卫光生物发布三季度报告，第三季度公司实现营业收入2.73亿元，同比下降 17.63%；归属于上市公司股东的净利润5021.42万元，同比下降31.06%。前三季度公司实现营业收入 7.91亿元，同比下降7.40%；前三季度归属于上市公司股东的净利润1.58亿元，同比下降13.60%。 ...

卫光生物公告，第三季度营收为2.73亿元，下降17.63%；净利润为5021.42万元，下降31.06%。前三季 度营收为7.91亿元，下降7.40%；净利润为1.58亿元，下降13.60%。 ...

1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 深圳市卫光生物制品股份有限公司 2025 年第三季度报告 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 证券代码：002880 证券简称：卫光生物 公告编号：2025-046 深圳市卫光生物制品股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 3.第三季度财务会计报告是否经过审计 □是 否 1 深圳市卫光生物制品股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 272,803,789.48 | -17. ...

Core Viewpoint - The company, Weigao Biologics, is progressing with its private placement plan to raise 1.5 billion yuan for expanding production capacity in the blood products sector, specifically to build a 1200-ton/year intelligent factory [2][3]. Group 1: Fundraising and Expansion Plans - Weigao Biologics plans to raise up to 1.5 billion yuan through a private placement, with 1.2 billion yuan allocated for the construction of an intelligent production base [3][4]. - The company aims to address its production capacity bottleneck, as its existing production line, established in 2013, has limited upgrade potential [3][6]. - The new factory will enable the production of various blood products, including human albumin and immunoglobulins, to meet increasing market demand [3][6]. Group 2: Historical Context and Financial Performance - Since its IPO in 2017, Weigao Biologics has raised only 678 million yuan, with previous fundraising attempts failing to materialize [2][5]. - The company has experienced fluctuating financial performance, with revenue dropping by 26.39% in 2022 due to the pandemic and production line upgrades, but rebounding in 2023 and 2024 with revenue growth of 56.98% and 14.75%, respectively [6][7]. - Cumulatively, Weigao Biologics has achieved a net profit of 1.577 billion yuan since its listing, maintaining a consistent dividend policy except for 2022 [7].

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]